Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 15/20 | 0.38 |
| ▸ | CNR1 | P21554 | 12/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15005386 | 0.98 | ESR1 (0.41) | ESR1CNR2CNR1HDAC1HDAC11 | |
| SCHEMBL22246056 | 0.98 | ESR1 (0.41) | ESR1CNR2CNR1HDAC1HDAC11 | |
| SCHEMBL11819809 | 0.98 | ESR1 (0.41) | ESR1CNR2CNR1HDAC1HDAC11 | |
| SCHEMBL3214672 | 0.98 | ESR1 (0.41) | ESR1CNR2CNR1HDAC1HDAC11 | |
| SCHEMBL7683272 | 0.94 | ESR1 (0.43) | ESR1CNR2CNR1HDAC1HDAC11 | |
| SCHEMBL18949950 | 0.86 | ESR1 (0.49) | ESR1CNR2CNR1ACLYCHRM3 | |
| SCHEMBL21507866 | 0.84 | ESR1 (0.41) | ESR1CNR2CNR1HDAC1HDAC11 | |
| SCHEMBL21191577 | 0.84 | ESR1 (0.41) | ESR1CNR2CNR1HDAC1HDAC11 | |
| SCHEMBL19204390 | 0.84 | ESR1 (0.41) | ESR1CNR2CNR1HDAC1HDAC11 | |
| SCHEMBL9557316 | 0.84 | ESR1 (0.41) | ESR1CNR2CNR1HDAC1HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220119384-A1 | POTENT ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-04-21 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787799-B2 | Potent antiviral pyrazolopyridine compounds | MAVS, VRK1, VRK2 | ESR1 4809/4885CNR2 3923/4885CNR1 3702/4885 |
| US-20220119384-A1 | POTENT ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS | MAVS, VRK1, VRK2 | ESR1 4809/4885CNR2 3923/4885CNR1 3702/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ESR1 1662/4885CNR2 2902/4885CNR1 2040/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | ESR1 1662/4885CNR2 2902/4885CNR1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.